Literature DB >> 18525345

Endpoints and surrogate endpoints in colorectal cancer: a review of recent developments.

Pascal Piedbois1, Marc Buyse.   

Abstract

PURPOSE OF REVIEW: The purpose of this review is to discuss recently published work on endpoints for early and advanced colorectal cancer, as well as the statistical approaches used to validate surrogate endpoints. RECENT
FINDINGS: Most attempts to validate surrogate endpoints have estimated the correlation between the surrogate and the true endpoint, and between the treatment effects on these endpoints. The correlation approach has made it possible to validate disease-free survival and progression-free survival as acceptable surrogates for overall survival in early and advanced disease, respectively.
SUMMARY: The search for surrogate endpoints will intensify over the coming years. In parallel, efforts to either standardize or extend the endpoints or both will improve the reliability and relevance of clinical trial results.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18525345     DOI: 10.1097/CCO.0b013e32830218fe

Source DB:  PubMed          Journal:  Curr Opin Oncol        ISSN: 1040-8746            Impact factor:   3.645


  8 in total

1.  Tumor status at 12 weeks predicts survival in advanced colorectal cancer: findings from NCCTG N9741.

Authors:  James M Heun; Axel Grothey; Megan E Branda; Richard M Goldberg; Daniel J Sargent
Journal:  Oncologist       Date:  2011-05-31

Review 2.  Biomarkers and surrogate end points--the challenge of statistical validation.

Authors:  Marc Buyse; Daniel J Sargent; Axel Grothey; Alastair Matheson; Aimery de Gramont
Journal:  Nat Rev Clin Oncol       Date:  2010-04-06       Impact factor: 66.675

Review 3.  Contributions of meta-analyses based on individual patient data to therapeutic progress in colorectal cancer.

Authors:  Marc Buyse
Journal:  Int J Clin Oncol       Date:  2009-04-24       Impact factor: 3.402

Review 4.  Benefit and harms of new anti-cancer drugs.

Authors:  Francisco E Vera-Badillo; Mustafa Al-Mubarak; Arnoud J Templeton; Eitan Amir
Journal:  Curr Oncol Rep       Date:  2013-06       Impact factor: 5.075

5.  Preclinical therapeutic response of residual metastatic disease is distinct from its primary tumor of origin.

Authors:  Chi-Ping Day; John Carter; Carrie Bonomi; Melinda Hollingshead; Glenn Merlino
Journal:  Int J Cancer       Date:  2011-04-20       Impact factor: 7.396

6.  A Weibull multi-state model for the dependence of progression-free survival and overall survival.

Authors:  Yimei Li; Qiang Zhang
Journal:  Stat Med       Date:  2015-04-10       Impact factor: 2.373

7.  The role of lung metastasis resection in improving outcome of colorectal cancer patients: results from a large retrospective study.

Authors:  Marco Tampellini; Azzurra Ottone; Elisa Bellini; Irene Alabiso; Chiara Baratelli; Raffaella Bitossi; Maria P Brizzi; Anna Ferrero; Elisa Sperti; Francesco Leone; Stefania Miraglia; Laura Forti; Erica Bertona; Francesco Ardissone; Alfredo Berruti; Oscar Alabiso; Massimo Aglietta; Giorgio V Scagliotti
Journal:  Oncologist       Date:  2012-09-06

8.  Implementation of AMNOG: An industry perspective.

Authors:  Friedhelm Leverkus; Christy Chuang-Stein
Journal:  Biom J       Date:  2015-09-01       Impact factor: 2.207

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.